Drug intelligence / Profile preview

JS214

Development stage
Unknown
Lead developer
Junshi Biosciences
Modality
Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

JS214 is a bispecific monoclonal antibody developed by Junshi Biosciences that simultaneously targets Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor-beta (TGF-β). This dual-targeting approach is designed to inhibit tumor angiogenesis by blocking VEGF signaling while simultaneously neutralizing the immunosuppressive effects of TGF-β within the tumor microenvironment. By addressing these two key pathways of tumor progression and immune evasion, JS214 aims to provide enhanced therapeutic efficacy in patients with advanced solid tumors. The drug is currently being evaluated in early-phase clinical trials to determine its safety, tolerability, and preliminary anti-tumor activity.

Other names
VEGF/TGF-β bispecific antibodyanti-VEGF/TGF-β bispecific antibody
02

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on JS214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS214.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call